30 Myalgic Encephalomyelitis Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Myalgic Encephalomyelitis Studies in Tucson

NCT04262206Recruiting

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in com...

Tucson, AZPHASE420,000 participantsDuke University

View Study Details

NCT06112418Recruiting

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no k...

Tucson, AZNA7,500 participantsCleerly, Inc.

View Study Details

NCT05918861Recruiting

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will prov...

Tucson, AZPHASE32,000 participantsDalCor Pharmaceuticals

View Study Details

NCT03678025Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer...

Tucson, AZPHASE31,273 participantsSWOG Cancer Research Network

View Study Details

NCT06066502Recruiting

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Particip...

Tucson, AZPHASE31,100 participantsBeth Israel Deaconess Medical Center

View Study Details

NCT07221357Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untre...

Tucson, AZPHASE2990 participantsBristol-Myers Squibb

View Study Details

NCT06747949Recruiting

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep....

Tucson, AZPHASE3844 participantsAmgen

View Study Details

NCT07044336Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or p...

Tucson, AZPHASE3800 participantsAstraZeneca

View Study Details

NCT06112314Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

Tucson, AZPHASE3680 participantsImmunocore Ltd

View Study Details

NCT06989112Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembroliz...

Tucson, AZPHASE3600 participantsAstraZeneca

View Study Details

NCT06246916Recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study i...

Tucson, AZPHASE3560 participantsRegeneron Pharmaceuticals

View Study Details

NCT07484217Recruiting

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal tr...

Tucson, AZPHASE3508 participantsAxsome Therapeutics, Inc.

View Study Details

NCT03460977Recruiting

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castra...

Tucson, AZPHASE1453 participantsPfizer

View Study Details

NCT04558541Recruiting

A Developmental Framework For Linking Phonological And Morpho-syntactic Sequential Pattern Rules In DLD: Production

The broad aim of this clinical study is to assess the hypothesis that morphological and phonological deficits are linked by a broader deficit in sequential pattern learning. This hypothesis applies to...

Tucson, AZNA400 participantsFather Flanagan's Boys' Home

View Study Details

NCT05640999Recruiting

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enroll...

Tucson, AZPHASE2393 participantsCanadian Cancer Trials Group

View Study Details

NCT05548296Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer....

Tucson, AZPHASE2350 participantsAcrivon Therapeutics

View Study Details

NCT06887192Recruiting

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucination...

Tucson, AZPHASE2300 participantsMapLight Therapeutics

View Study Details

NCT07210515Recruiting

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

Phase 3 Trial of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1...

Tucson, AZPHASE3270 participantsAmbros Therapeutics, Inc.

View Study Details

NCT07198074Recruiting

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizuma...

Tucson, AZPHASE3255 participantsNational Cancer Institute (NCI)

View Study Details

NCT03550391Recruiting

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to s...

Tucson, AZPHASE3206 participantsCanadian Cancer Trials Group

View Study Details

NCT07527910Recruiting

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MA...

Tucson, AZPHASE2204 participantsRegeneron Pharmaceuticals

View Study Details

NCT07195734Recruiting

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by pos...

Tucson, AZPHASE2180 participantsNational Cancer Institute (NCI)

View Study Details

NCT06524830Recruiting

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatm...

Tucson, AZPHASE2142 participantsatai Therapeutics, Inc.

View Study Details

NCT07002034Recruiting

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adj...

Tucson, AZPHASE2100 participantsReunion Neuroscience Inc

View Study Details

NCT07287917Recruiting

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: ...

Tucson, AZPHASE192 participantsAminex Therapeutics, Inc.

View Study Details

NCT07286305Recruiting

Media and Mental Health

This study's goal is to find if using the ThinkHumanTV program during 6 weekly sessions of watching Netflix or Disney series or movies for 90 minutes, together with 4 - 8 members of the Whole Health C...

Tucson, AZNA70 participantsUniversity of Arizona

View Study Details

NCT06394830Recruiting

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via cathet...

Tucson, AZPHASE250 participantsVaneltix Pharma, Inc.

View Study Details

NCT07303998Recruiting

Remote tDCS and Chair Yoga for Chronic Knee Pain in Alzheimer's Patients

This study aims to evaluate the feasibility, acceptability, and preliminary effects of a home-based, remotely supervised intervention combining transcranial direct current stimulation (tDCS) and onlin...

Tucson, AZNA40 participantsUniversity of Arizona

View Study Details

NCT06814496Recruiting

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radi...

Tucson, AZPHASE130 participantsUniversity of Arizona

View Study Details

NCT06055790Recruiting

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

The goal of this diagnostic intervention clinical trial is to compare 18F-Fluciclovine uptake within brain lesions over 60 minutes compared with standard of care positive histology confirmation or con...

Tucson, AZEARLY_PHASE120 participantsUniversity of Arizona

View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Tucson

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 30 myalgic encephalomyelitis clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 40,410 participants. Research is being sponsored by Duke University, Cleerly, Inc., DalCor Pharmaceuticals and 20 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Tucson — FAQ

Are there myalgic encephalomyelitis clinical trials in Tucson?

Yes, there are 30 myalgic encephalomyelitis clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 30 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated October 16, 2026 from ClinicalTrials.gov